Release
📈 Stocks
Bold Therapeutics Hits 60-Patient Enrollment Milestone in Phase 2 Cancer Trial
(just now)
Bold Therapeutics reaches the 60-patient enrollment midpoint in its Phase 2 trial for BOLD-100, advancing its clinical development pipeline for novel metallotherapeutics.